ReviewTherapeutics and clinical risk management2015
Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists.
Review in Therapeutics and clinical risk management, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Comparative efficacy of pharmacologic interventions in ulcerative colitis: a network meta analysis.Inflammopharmacology · 2025Pooled it
- Prevalence and clinical implications of anti-drug antibody formation and serum drug levels among patients with IBD receiving anti-TNF therapy: A cross-sectional study.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2025Article
- Current Approaches to Ulcerative Colitis Management: A Comprehensive Overview of Methodologies and Treatments.Infectious disorders drug targets · 2025Review
- An integrated machine learning framework for developing and validating diagnostic models and drug predictions based on ulcerative colitis genes.Frontiers in medicine · 2025Article
- Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis: post-marketing surveillance study.BMC gastroenterology · 2024Observational
- The gut barrier as a gatekeeper in colorectal cancer treatment.Oncotarget · 2024Review
- Medical Treatment Options for Ulcerative Colitis.Clinics in colon and rectal surgery · 2022Review
- Acute oral treatment with resveratrol and Lactococcus Lactis Subsp. Lactis decrease body weight and improve liver proinflammatory markers in C57BL/6 mice.Molecular biology reports · 2021Article
- Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases.World journal of gastrointestinal pathophysiology · 2020Review
- Anti-tumor necrosis factor agents and COVID-19: A word of caution.Journal of clinical and translational research · 2020Article
- Intrarectally administered polaprezinc attenuates the development of dextran sodium sulfate-induced ulcerative colitis in mice.Experimental and therapeutic medicine · 2019Article
- Evaluation of Gastrointestinal Patient Reported Outcomes Measurement Information System (GI-PROMIS) Symptom Scales in Subjects With Inflammatory Bowel Diseases.The American journal of gastroenterology · 2018Article
- Second-generation Flagellin-rPAc Fusion Protein, KFD2-rPAc, Shows High Protective Efficacy against Dental Caries with Low Potential Side Effects.Scientific reports · 2017Article
- Dynamics of Th17 associating cytokines in Cryptosporidium parvum-infected mice.Parasitology research · 2016Article
- Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management.Clinical and translational gastroenterology · 2016Article
- Article
- Emerging Treatment Options in Mild to Moderate Ulcerative Colitis.Gastroenterology & hepatology · 2015Article
- Inflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological Treatments.Mediators of inflammation · 2015Review
- Early discontinuation of biological therapy among inflammatory bowel disease patients in Bahrain: Real world experience.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis can cause debilitating symptoms and complications such as colonic strictures, colonic dysplasia, colorectal cancer, and toxic megacolon or perforation. Goals of treatment in ulcerative colitis include resolution of gastrointestinal symptoms, healing of colonic mucosa, and prevention of disease complications. Our treatment armamentarium has expanded dramatically over the past 10 years, and we now have multiple biologic agents approved for the treatment of moderate-severe disease, in addition to conventional therapies such as 5-aminosalicylates, thiopurines, and corticosteroids. In this review, we will provide a detailed discussion of the three tumor necrosis factor-alpha (TNF-α) inhibitors currently approved for treatment of ulcerative colitis: infliximab, adalimumab, and golimumab. All three agents are effective for inducing and maintaining clinical response and remission in patients with ulcerative colitis, and they have comparable safety profiles. There are no head-to-head trials comparing their efficacy, and the choice of agent is most often based on insurance coverage, route of administration, and patient preference. Combination therapy with an immunomodulator is proven to be more effective than anti-TNF monotherapy, and patients who lose response to an anti-TNF agent should undergo dose intensification in order to regain clinical response. Despite therapeutic optimization, a significant percentage of patients will not achieve clinical remission with anti-TNF agents, and so newer therapies are on the horizon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.